GlassScriptPhysician profile
Aneesa Krishnamurthy
NPI 1386891604
$3,593.11
in general payments reported to CMS, 2019-2025
24 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,956 · 2020: $319 · 2021: $557 · 2022: $42.69 · 2023: $251 · 2024: $332 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.01 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $731.45 | 2019-2025 | |
| Amgen INC. | $412.11 | 2019-2025 | Prolia, Evenity, Krystexxa |
| Glaxosmithkline, LLC. | $302.71 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $179.64 | 2019-2023 | Tremfya |
| Celgene Corporation | $152.56 | 2019 | |
| Ucb, INC. | $149.11 | 2019-2025 | Bimzelx |
| Genzyme Corporation | $148.68 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.61 | 2021-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $135.12 | 2021 | |
| Lilly USA, LLC | $134.37 | 2019 | |
| Sanofi-Aventis U.S. LLC | $132.25 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $127.27 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $122.80 | 2020 | |
| Abbvie INC. | $108.07 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $107.07 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $99.29 | 2019-2023 | |
| Genentech USA, INC. | $95.20 | 2019 | |
| Radius Health, INC. | $91.90 | 2019-2023 | |
| Horizon Therapeutics Plc | $88.65 | 2019-2023 | Krystexxa |
| Zimmer Biomet Holdings, INC. | $36.65 | 2019-2020 | |
| Sobi, INC | $28.16 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $22.40 | 2023 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $20.79 | 2021 | |
| Daiichi Sankyo INC. | $19.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneesa Krishnamurthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.